Thyroid Cancer

Cancer doesn’t discriminate. It doesn’t care what race, gender, ethnicity, sexuality or even age you are. It takes no prisoners. And it certainly did not take me. I continue to remain resilient despite what I’ve been through and despite what still may be on the horizon.

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

As a result of what I went through and my never-ending passion for helping others, I believe that my diagnosis happened for a reason – to lead me to a career in patient advocacy.

Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.

The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

From genetic mutations to treatment behind bars, here's a roundup of our 2018 Summer issue.

In this week’s episode of CURE Talks Cancer, we spoke with Voigt about how he noticed a lump in a woman’s neck while watching tv and utilized the power of social media to find her – which ultimately led to a thyroid cancer diagnosis.

Instead of undergoing surgery for potential cancer, many people with thyroid nodules can safely opt for surveillance.

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.